Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US patent office rejects claims on Forest's Bystolic

This article was originally published in Scrip

Executive Summary

Forest Laboratoriessaid that during a re-examination the US Patent and Trademark Officerejected claims on a US patent, No 6,545,040, covering its beta-blocker product Bystolic (nebivolol). The company said that the PTO rejected all claims on the active ingredient as unpatentable in view of the cited prior art. "We believe the claims are patentable over the cited art and we will continue to prosecute the re-examination application," Forest stated. Forest licensed the US and Canadian rights to Bystolic from Mylan, and Mylan had licensed the rights from Janssen (Johnson & Johnson). Janssen submitted the patent for re-examination by the government last year. Natixis Bleichroeder analysts have stated that, in a worst-case scenario, the decision could result in Bystolic facing generic competition as early as 2015 instead of 2022.

UsernamePublicRestriction

Register

SC002775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel